Evidence map›Paper›PMID 38298115›Full record

ArticleCancer medicine2024

Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: A scoping review.

Theresia Pichler, Friederike Mumm, Navdeep Dehar, Erin Dickman, Celia Díez de Los Ríos de la Serna, Andreas Dinkel, Kathrin Heinrich, Merel Hennink, Anndra D Parviainen, Vincent Raske and 2 more

Open access · goldAbstract readScoping Review
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

Theresia PichlerDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0001-5569-1249
Friederike MummDepartment of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-0026-7779
Navdeep DeharDepartment of Medical Oncology, Queen's University, Kingston, Ontario, Canada.ORCID 0000-0002-9534-6738
Erin DickmanOncology Nursing Society, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-8014-5116
Celia Díez de Los Ríos de la SernaEuropean Oncology Nursing Society, Brussels, Belgium.ORCID 0000-0003-2630-2106
Andreas DinkelDepartment of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0000-0001-6587-1550
Kathrin HeinrichComprehensive Cancer Center Munich LMU (CCC Munich), Munich, Germany.ORCID 0000-0003-3580-2313
Merel HenninkStichting Merels Wereld, Groningen, The Netherlands.
Anndra D ParviainenDepartment of Nursing Science, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0001-5979-0826
Vincent RaskeThe Synergist, Brussels, Belgium.
Nicole WickiThe Synergist, Brussels, Belgium.ORCID 0000-0003-2609-7376
Amy C MooreLUNGevity Foundation, Chicago, Illinois, USA.
LMU Klinikum · DESynergetics (Belgium) · BEEuropean Society for Paediatric Oncology · BELUNGevity Foundation · USMarti-Keuning Eckhardt Stichting · NLOncology Nursing Society · USQueen's University · CATUM Klinikum · DEUniversity of Eastern Finland · FI

Funding

From Testing to Targeted Treatments (FT3) Program
6 · The paper itself

Abstract

backgroundPrecision oncology, using comprehensive biomarker testing (cBT) to inform individual cancer diagnosis, prognosis and treatment, includes increasingly complex technology and clinical data sets. People impacted by cancer (patients and caregivers) and healthcare professionals (HCPs) face distinct challenges in navigating the cBT and personalized treatment landscape. This review summarizes evidence regarding cBT-related communication between people impacted by cancer and HCPs and identifies important avenues for future research in precision oncology.

methodsA scoping review was conducted using records published in PubMed during January 2017-August 2022, focusing on the breadth of topics on patient-HCP communication and knowledge resources used by HCPs as guidance in cBT-related communication. Data were extracted from records meeting inclusion criteria, and findings were summarized according to main topics.

resultsThe search identified 287 unique records and data were extracted from 42 records, including nine from expert input. Most records originated from the United States included patients with different types of cancer, and oncologists were the main HCPs. Patients' motivation for undergoing cBT and receiving results was generally high in different settings. However, patients' understanding of cBT-related concepts was limited, and their knowledge and information preferences changed based on cBT implications and significance to family members. HCPs were valued by patients as a trusted source of information. Limited evidence was available on HCPs' information-seeking behavior and factors influencing cBT-related knowledge and confidence, often self-reported as insufficient.

conclusionsPatient education by knowledgeable and confident HCPs, information management and a caring patient-HCP relationship communicating continuity of care regardless of cBT results are crucial to empower patients and shared decision-making in precision oncology. More data on the process and structure of cBT-related communication, distinction between and characterization of different timepoints of patient-HCP interactions are needed.

Indexed as

NeoplasmsBiomarkersCommunicationDelivery of Health CareHumansPrecision MedicineBiomarkersbiomarkerscommunicationdecision making, sharedneoplasmsphysician-patient relationsprecision medicinepsycho-oncology

Identifiers

PMID38298115
PMCPMC10905543
OpenAlexW4391442552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.